34.74
0.12%
0.04
Dopo l'orario di chiusura:
34.74
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SUPN Giù?
Forum
Previsione
Precedente Chiudi:
$34.70
Aprire:
$39.37
Volume 24 ore:
937.64K
Relative Volume:
2.39
Capitalizzazione di mercato:
$1.91B
Reddito:
$597.40M
Utile/perdita netta:
$-15.51M
Rapporto P/E:
47.59
EPS:
0.73
Flusso di cassa netto:
$99.84M
1 W Prestazione:
+1.05%
1M Prestazione:
+8.49%
6M Prestazione:
+12.68%
1 anno Prestazione:
+41.91%
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Nome
Supernus Pharmaceuticals Inc
Settore
Telefono
301-838-2500
Indirizzo
9715 KEY WEST AVENUE, ROCKVILLE, MD
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2023-01-03 | Ripresa | Jefferies | Buy |
2021-12-01 | Ripresa | Jefferies | Buy |
2021-04-13 | Aggiornamento | Jefferies | Hold → Buy |
2020-06-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
2020-06-15 | Ripresa | Jefferies | Hold |
2019-11-08 | Downgrade | Berenberg | Buy → Hold |
2019-11-07 | Downgrade | Stifel | Buy → Hold |
2019-11-06 | Downgrade | Jefferies | Buy → Hold |
2018-11-12 | Reiterato | B. Riley FBR | Buy |
2018-01-18 | Reiterato | B. Riley FBR, Inc. | Buy |
2017-12-28 | Reiterato | B. Riley FBR, Inc. | Buy |
2017-12-04 | Aggiornamento | Janney | Neutral → Buy |
2017-11-08 | Aggiornamento | Stifel | Hold → Buy |
2017-10-19 | Iniziato | FBR & Co. | Buy |
2017-09-19 | Downgrade | Stifel | Buy → Hold |
2017-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
2017-07-14 | Iniziato | Janney | Neutral |
2017-06-01 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
2016-07-18 | Downgrade | Northland Capital | Outperform → Market Perform |
2016-07-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
2016-02-08 | Aggiornamento | Jefferies | Hold → Buy |
2015-11-05 | Reiterato | Northland Capital | Outperform |
2015-10-28 | Iniziato | Northland Capital | Outperform |
Mostra tutto
Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie
Earnings call: Supernus Pharmaceuticals reported a significant increase in total revenue - Investing.com
Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 1-Year High Following Earnings Beat - MarketBeat
Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highli - GuruFocus.com
Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates - MSN
Supernus Pharmaceuticals Reports Strong Q3 2024 Results - TipRanks
Supernus Pharmaceuticals Q3 2024 Earnings: EPS of $0.69 Beats Es - GuruFocus.com
Supernus Announces Third Quarter 2024 Financial Results - GlobeNewswire
Supernus Pharmaceuticals (NASDAQ:SUPN) Issues Earnings Results - MarketBeat
Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Supernus Pharmaceuticals (FRA:S49) PE Ratio : 387.50 (As of Nov. 04, 2024) - GuruFocus.com
Supernus: Q3 Earnings Snapshot - The Washington Post
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
(SUPN) On The My Stocks Page - Stock Traders Daily
Macquarie Group Ltd Adjusts Stake in Supernus Pharmaceuticals Inc - GuruFocus.com
Stephens Investment Management Group LLC Buys 33,710 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Dimensional Fund Advisors LP Expands Stake in Supernus Pharmaceu - GuruFocus.com
Supernus Presents Promising Data from Open-Label Phase 2a - GlobeNewswire
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024 - Yahoo Finance
Supernus Pharmaceuticals reports rapid depression treatment response By Investing.com - Investing.com Australia
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Could Signal Some Risk - Simply Wall St
Supernus Pharmaceuticals reports rapid depression treatment response - Investing.com India
Supernus Pharmaceuticals (SUPN) Scheduled to Post Quarterly Earnings on Monday - MarketBeat
Attention Deficit Hyperactivity Disorder Market Projected - openPR
Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results - The Manila Times
Supernus Pharmaceuticals to Host Conference Call and - GlobeNewswire
Supernus Pharmaceuticals (NASDAQ:SUPN) Reaches New 12-Month HighTime to Buy? - MarketBeat
Exchange Traded Concepts LLC Makes New Investment in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus’ depression drug improved symptoms in two hours in Phase IIa study - Clinical Trials Arena
Supernus stock holds Buy rating on MDD trial data By Investing.com - Investing.com UK
Supernus Announces Promising Data from Open-Label Phase 2a - GlobeNewswire
Supernus reports Phase 2a data for SPN-820, stock climbs 6% - MSN
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with - The Bakersfield Californian
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder - StockTitan
SUPN (Supernus Pharmaceuticals) 3-Year EPS without NRI Grow - GuruFocus.com
(SUPN) Trading Signals - Stock Traders Daily
Millennium Management LLC Buys 128,743 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder - The Manila Times
Supernus Pharmaceuticals to Host Webcast to Review - GlobeNewswire
Supernus Pharmaceuticals Inc (SUPN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Supernus Pharmaceuticals Inc (SUPN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Healthcare of Ontario Pension Plan Trust Fund Buys Shares of 40,000 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Marshall Wace LLP Acquires Shares of 73,519 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
(SUPN) Technical Data - Stock Traders Daily
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Bank of Montreal Can - MarketBeat
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Purchased by Dimensional Fund Advisors LP - MarketBeat
Armistice Capital LLC Has $141.03 Million Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Pulling back 3.6% this week, Supernus Pharmaceuticals' NASDAQ:SUPN) five-year decline in earnings may be coming into investors focus - Simply Wall St
Busy Philipps Encourages Women to Take Charge of Their ADHD - GlobeNewswire
Supernus Pharmaceuticals Inc Azioni (SUPN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Supernus Pharmaceuticals Inc Azioni (SUPN) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
GEMAYEL GEORGES | Director |
Sep 13 '24 |
Sale |
31.33 |
13,886 |
435,048 |
13,315 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):